サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1387209

アダリムマブバイオシミラー市場レポート：2030年までの動向、予測、競合分析

Adalimumab Biosimilar Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

アダリムマブバイオシミラー市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年10月30日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

アダリムマブバイオシミラーの動向と予測

世界のアダリムマブバイオシミラー市場は、2024年から2030年までのCAGRが21.6%で、2030年までに推定27億9,000万米ドルに達すると予測されます。この市場の主な促進要因は、皮膚疾患の増加とともに関節炎薬の罹患率が高まっていることです。世界のアダリムマブバイオシミラー市場の将来は、病院薬局と小売薬局市場に機会があり、有望視されています。

アダリムマブバイオシミラー市場の洞察

Lucintel社の予測では、予測期間中に最も高い成長が見込まれるのはエクセンプティアです。

アダリムマブバイオシミラー製剤は様々な自己免疫疾患の治療に使用され、一般的に病院内の専門医によって管理されるためです。

北米は、高齢者人口の増加とともに関節リウマチの有病率が高まっていることから、予測期間中も最大地域であり続けるでしょう。

本レポートでは、以下の11の主要な質問に回答しています：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界のアダリムマブバイオシミラー市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のアダリムマブバイオシミラー市場動向（2018-2023）と予測（2024-2030）
  • 製品別の世界のアダリムマブバイオシミラー市場
    • Exemptia
    • Adalirel
    • Cipleumab
    • その他
  • 最終用途別の世界のアダリムマブバイオシミラー市場
    • 病院薬局
    • 小売薬局
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のアダリムマブバイオシミラー市場
  • 北米のアダリムマブバイオシミラー市場
  • 欧州のアダリムマブバイオシミラー市場
  • アジア太平洋アダリムマブバイオシミラー市場
  • その他地域アダリムマブバイオシミラー市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 製品別の世界のアダリムマブバイオシミラー市場の成長機会
    • 最終用途別の世界のアダリムマブバイオシミラー市場の成長機会
    • 地域別の世界のアダリムマブバイオシミラー市場の成長機会
  • 世界のアダリムマブバイオシミラー市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のアダリムマブバイオシミラー市場の生産能力拡大
    • 世界のアダリムマブバイオシミラー市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences
目次

Adalimumab Biosimilar Trends and Forecast

The future of the global adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets. The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030 with a CAGR of 21.6% from 2024 to 2030. The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.

A more than 150-page report is developed to help in your business decisions.

Adalimumab Biosimilar by Segment

The study includes a forecast for the global adalimumab biosimilar by product, end use, and region.

Adalimumab Biosimilar Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

Adalimumab Biosimilar Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Others

Adalimumab Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Adalimumab Biosimilar Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adalimumab biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adalimumab biosimilar companies profiled in this report include-

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences

Adalimumab Biosimilar Market Insights

Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.

Within this market, hospitals pharmacies is expected to remain the largest segment due to the fact that adalimumab biosimilars are used to treat a variety of autoimmune diseases, which are typically managed by specialists in hospital settings.

North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.

Features of the Global Adalimumab Biosimilar Market

Market Size Estimates: Adalimumab biosimilar market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Adalimumab biosimilar market size by product, end use, and region in terms of value ($B).

Regional Analysis: Adalimumab biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different products, end uses, and regions for the adalimumab biosimilar market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adalimumab biosimilar market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the adalimumab biosimilar market size?

Answer: The global adalimumab biosimilar market is expected to reach an estimated $2.79 billion by 2030.

Q2. What is the growth forecast for adalimumab biosimilar market?

Answer: The global adalimumab biosimilar market is expected to grow with a CAGR of 21.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the adalimumab biosimilar market?

Answer: The major drivers for this market are the growing incidence of arthritis drugs along with rising number of skin disorders.

Q4. What are the major segments for adalimumab biosimilar market?

Answer: The future of the adalimumab biosimilar market looks promising with opportunities in the hospitals pharmacy and retail pharmacy markets.

Q5. Who are the key adalimumab biosimilar market companies?

Answer: Some of the key adalimumab biosimilar companies are as follows:

  • Alfred E. Tiefenbacher
  • Amgen
  • Boehringer Ingelheim
  • Glenmark
  • Zydus
  • Torrent Pharmaceuticals
  • Reliance Life Sciences

Q6. Which adalimumab biosimilar market segment will be the largest in future?

Answer: Lucintel forecasts that exemptia is expected to witness the highest growth over the forecast period.

Q7. In adalimumab biosimilar market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to the growing prevalence of rheumatoid arthritis along with the rise in the geriatric population.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the adalimumab biosimilar market by product (exemptia, adalirel, cipleumab, and others), end use (hospitals pharmacies, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Adalimumab Biosimilar Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Adalimumab Biosimilar Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Adalimumab Biosimilar Market by Product
    • 3.3.1: Exemptia
    • 3.3.2: Adalirel
    • 3.3.3: Cipleumab
    • 3.3.4: Others
  • 3.4: Global Adalimumab Biosimilar Market by End Use
    • 3.4.1: Hospitals Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Adalimumab Biosimilar Market by Region
  • 4.2: North American Adalimumab Biosimilar Market
    • 4.2.2: North American Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.3: European Adalimumab Biosimilar Market
    • 4.3.1: European Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.3.2: European Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.4: APAC Adalimumab Biosimilar Market
    • 4.4.1: APAC Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.4.2: APAC Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others
  • 4.5: ROW Adalimumab Biosimilar Market
    • 4.5.1: ROW Adalimumab Biosimilar Market by Product: Exemptia, Adalirel, Cipleumab, and Others
    • 4.5.2: ROW Adalimumab Biosimilar Market by End Use: Hospitals Pharmacies, Retail Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Adalimumab Biosimilar Market by Product
    • 6.1.2: Growth Opportunities for the Global Adalimumab Biosimilar Market by End Use
    • 6.1.3: Growth Opportunities for the Global Adalimumab Biosimilar Market by Region
  • 6.2: Emerging Trends in the Global Adalimumab Biosimilar Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Adalimumab Biosimilar Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adalimumab Biosimilar Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Alfred E. Tiefenbacher
  • 7.2: Amgen
  • 7.3: Boehringer Ingelheim
  • 7.4: Glenmark
  • 7.5: Zydus
  • 7.6: Torrent Pharmaceuticals
  • 7.7: Reliance Life Sciences